Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **immediate-early 1 protein (IE1)** is a multifunctional viral regulatory protein encoded by cytomegaloviruses, a subgroup of betaherpesviruses, including human cytomegalovirus (HCMV)[1][2][3][4]. **IE1 is abundantly produced during the earliest phase of viral infection, preceding the expression of early and late genes.** It acts primarily in the host cell nucleus, where it targets host chromatin by binding directly to core histones, modifies chromatin structure, and regulates both viral and cellular gene expression—acting as both an activator and repressor of transcription[3][4]. IE1 plays a well-defined role in viral immune evasion by directly antagonizing the cellular restriction factor promyelocytic leukemia protein (PML) and dismantling PML nuclear bodies, thus overcoming intrinsic antiviral defenses[2]. Moreover, IE1 interacts with and redirects host cell signaling: it disrupts IL6-mediated STAT3 signaling to activate STAT1-dependent transcription, reshaping cytokine responses to benefit viral pathogenesis[4]. Structurally, IE1 proteins form a unique, highly conserved tertiary and quaternary configuration with species-specific adaptations, facilitating efficient PML targeting within their natural host[2][3]. Although IE1 is essential for viral replication and immune modulation, **it is not considered a therapeutic target in the conventional sense (such as a receptor, enzyme, or transporter), and no approved drugs act directly on IE1.** IE1 protein or antibodies against it may serve as evidence of active or latent cytomegalovirus infection but are not currently used as clinical biomarkers for treatment selection or monitoring[3]. **Note:** "Immediate-early 1 protein" is specific to cytomegaloviruses and is not a human gene product. This makes it distinct from conventional drug targets, most of which are endogenous human proteins. There is no direct evidence that IE1 is the target of any approved antiviral agents, and no small-molecule inhibitors for clinical use are currently known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immediate-early 1 protein (IE1).